Olu­mi­ant from Lil­ly, In­cyte clears third eczema study, but who will use it?

Months ago In­cyte $IN­CY elect­ed to stop fund­ing the de­vel­op­ment of Olu­mi­ant (baric­i­tinib) — com­ing up with those funds be­came part­ner Eli Lil­ly’s prob­lem. The JAK in­hibitor, which has been dogged by safe­ty con­cerns, has now cleared an­oth­er late-stage atopic der­mati­tis (AD) study.

In June 2018, the FDA ap­proved on­ly the small 2 mg dose of the drug for rheuma­toid arthri­tis, with a black box warn­ing high­light­ing the ther­a­py’s side ef­fects, in­clud­ing a star­tling throm­boem­bolism sig­nal, quash­ing Lil­ly’s $LLY block­buster dreams. The agency had ini­tial­ly re­ject­ed the drug, de­mand­ing a new study, but un­der the lead­er­ship of (now for­mer) FDA com­mis­sion­er Scott Got­tlieb, the FDA had an in­ex­plic­a­ble change of heart, and al­lowed the mar­ket­ing ap­pli­ca­tion to pro­ceed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER